Effect of TF-TAVR on Emotional Status, Quality of Life, Frailty and Inflammation

Sponsor
Medical University of Graz (Other)
Overall Status
Unknown status
CT.gov ID
NCT03308435
Collaborator
(none)
102
1
37.8
2.7

Study Details

Study Description

Brief Summary

Aortic valve stenosis (AS) shows high and increasing prevalence in Western civilizations and leads to high morbidity and mortality. 15 years ago Alain Cribier performed the first catheter-based transfemoral aortic valve replacement at the University of Rouon. This historical step initiated a dramatic shift in the treatment of AS with more than 50% of patients being treated interventionally instead of the surgical approach, today.

Comorbidities are major determinants of cardiovascular events and clinical outcome in aortic valve stenosis but little is known about psychiatric comorbidities or frailty in these patients. Data from our group suggest an inflammatory trigger for depression and potentially other psychiatric diseases and aortic valve stenosis as well as aortic valve replacement are associated with considerable changes in the inflammatory state of the patients. However, no study has prospectively examined the interaction of these inflammatory markers and mood disorders, yet. In addition, frailty is a key aspect of many of TAVR patients clinically, however, scientifically there is only emerging data with half of all PubMed-indexed publications being less than 18 months old and clinical use of various scores still under discussion.

The " Effect of interventional aortic valve replacement on emotional status, quality of life, frailty and inflammation"-study is designed to fill these gaps in evidence. It will be a prospective epidemiological cohort study to recruit 102 patients with symptomatic severe aortic valve stenosis within 18 months. All of these patients will undergo standardized cardiologic, psychiatric and frailty assessment as well as a sophisticated laboratory analysis focussing on the inflammatory state. The study aims to integrate these interdisciplinary findings to optimize patient treatment.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Geriatric assessment
  • Diagnostic Test: Psychiatric assessment
  • Diagnostic Test: Inflammatory assessment
  • Diagnostic Test: Cardiological assessment

Detailed Description

Aortic valve stenosis (AS) shows a high prevalence in Western civilizations with an increasing incidence and is associated with high morbidity and mortality. AS is a degenerative disease and therefore the main reason for the increasing prevalence is the higher proportion of elderly patients in western societies. Untreated symptomatic AS is characterized by severe morbidity with mainly dyspnea, orthopnea and reduced exercise capacity. In addition, AS has a very high mortality (50-90% in 2 years), most often due to lung edema as a result of increased afterload of the left ventricle. So far, there is no medical treatment available improving mortality in these patients. For decades, the only known therapy has been surgical aortic valve replacement (SAVR), having shown a dramatic reduction in mortality. However, many of the patients suffering from AS are octogenarians or even older and also suffer from multiple comorbidities. Thus, many of these patients are considered inoperable using a surgical approach. Exactly 15 years ago Alain Cribier performed the first catheter-based transfemoral aortic valve replacement at the University of Rouon. This historical step initiated a dramatic shift in the treatment of AS with more than 50% of patients being treated interventionally instead of the surgical approach, today.

Comorbidities are major determinants of cardiovascular events and clinical outcome in aortic valve stenosis but little is known about psychiatric comorbidities or frailty in these patients. Data from our group suggest an inflammatory trigger for depression and potentially other psychiatric diseases and aortic valve stenosis as well as aortic valve replacement are associated with considerable changes in the inflammatory state of the patients. However, no study has prospectively examined the interaction of these inflammatory markers and mood disorders, yet. In addition, frailty is a key aspect of many of TAVR patients clinically, however, scientifically there is only emerging data with half of all PubMed-indexed publications being less than 12 months old and clinical use of various scores still under discussion.

The " Effect of interventional aortic valve replacement on emotional status, quality of life, frailty and inflammation"-study is designed to fill these gaps in evidence. It will be a prospective epidemiological cohort study to recruit 102 patients with symptomatic severe aortic valve stenosis within 18 months. All of these patients will undergo standardized cardiologic, psychiatric and frailty assessment as well as a sophisticated laboratory analysis focussing on the inflammatory state. The study aims to integrate these interdisciplinary findings to optimize patient treatment.

Study Design

Study Type:
Observational
Anticipated Enrollment :
102 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Effect of Transfemoral Transcatheter Aortic Valve Replacement (TF-TAVR) on Emotional Status, Quality of Life, Frailty and Inflammation and Their Interactions
Actual Study Start Date :
Nov 6, 2017
Anticipated Primary Completion Date :
Dec 31, 2020
Anticipated Study Completion Date :
Dec 31, 2020

Outcome Measures

Primary Outcome Measures

  1. Aortic valve area [6 months]

    valve area as measured calculated by doppler echocardiography

Secondary Outcome Measures

  1. HAMD-17 (Hamilton) [6 months]

    questionaire score

  2. BDI-II [6 months]

    Beck depression inventory score

  3. SF-36 [6 months]

    short form-36 questionaire

  4. PTSS-10 [6 months]

    Post traumatic syndrome scale-10

  5. Euro-QoL5D [6 Months]

    Quality of life questionaire

  6. hand grip strenght test [6 months]

    hand grip strenght test

  7. BIA [6 Months]

    Bioelectrical impedance analysis

  8. kynurenine acid [6 months]

    inflammatory marker

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Symptomatic aortic valve stenosis

  • Planned elective transcatheter aortic valve replacement

  • Willingness and ability to provide signed informed consent (IC) form prior to participation in any study-related procedures

Exclusion Criteria:
  • Disease reducing life expectancy to < 1 year

  • Severe immune-system modulating or -affecting disease

Contacts and Locations

Locations

Site City State Country Postal Code
1 Medical University of Graz Graz Austria 8010

Sponsors and Collaborators

  • Medical University of Graz

Investigators

  • Principal Investigator: Dirk von Lewinski, MD, Medical University of Graz

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dirk von Lewinski, Assoc. Prof., Medical University of Graz
ClinicalTrials.gov Identifier:
NCT03308435
Other Study ID Numbers:
  • 29-371 ex 16/17
First Posted:
Oct 12, 2017
Last Update Posted:
Mar 25, 2019
Last Verified:
Mar 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 25, 2019